| 前收市價 | 6,629.00 |
| 開市 | 6,630.00 |
| 買盤 | 6,584.00 x 0 |
| 賣出價 | 6,593.00 x 0 |
| 今日波幅 | 6,581.00 - 6,680.00 |
| 52 週波幅 | 5,795.00 - 10,015.00 |
| 成交量 | |
| 平均成交量 | 1,274,541 |
| 市值 | 1.9T |
| Beta 值 (5 年，每月) | -0.06 |
| 市盈率 (最近 12 個月) | 44.84 |
| 每股盈利 (最近 12 個月) | 147.00 |
| 業績公佈日 | 2024年7月31日 - 2024年8月05日 |
| 遠期股息及收益率 | 160.00 (2.41%) |
| 除息日 | 2024年9月27日 |
| 1 年預測目標價 | 7,882.30 |
Yahoo FinanceAlzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form
An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.
Yahoo FinanceNew Alzheimer's drug success 'was built on failures': Eisai exec
Eisai just reached the finish line with its long-fought battle to gain Medicare approval for Alzheimer's drug Leqembi. But the company says more work remains.
Yahoo FinanceNew Alzheimer's drug from Biogen, Eisai gets government approval, but faces long road ahead
Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight.
